• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC Med Res Methodol . CalScope: methodology and lessons learned for conducting a remote statewide SARS-CoV-2 seroprevalence study in California usi

tetano

Editor, Senior Moderator
BMC Med Res Methodol


. 2024 May 27;24(1):120.
doi: 10.1186/s12874-024-02245-y. CalScope: methodology and lessons learned for conducting a remote statewide SARS-CoV-2 seroprevalence study in California using an at-home dried blood spot collection kit and online survey

Esther Lim[SUP] 1 [/SUP], Megha L Mehrotra[SUP] 2 [/SUP], Katherine Lamba[SUP] 2 [/SUP], Amanda Kamali[SUP] 2 [/SUP], Kristina W Lai[SUP] 2 [/SUP], Erika Meza[SUP] 2 [/SUP], Stephanie Bertsch-Merbach[SUP] 2 [/SUP], Irvin Szeto[SUP] 3 [/SUP], Catherine Ley[SUP] 4 [/SUP], Andrew B Martin[SUP] 3 [/SUP], Julie Parsonnet[SUP] 4 [/SUP], Peter Robinson[SUP] 5 [/SUP], David Gebhart[SUP] 5 [/SUP], Noemi Fonseca[SUP] 5 [/SUP], Cheng-Ting Tsai[SUP] 5 [/SUP], David Seftel[SUP] 5 [/SUP], Allyx Nicolici[SUP] 2 [/SUP], David Melton[SUP] 2 [/SUP], Seema Jain[SUP] 2 [/SUP]



Affiliations
Abstract

Background: To describe the methodology for conducting the CalScope study, a remote, population-based survey launched by the California Department of Public Health (CDPH) to estimate SARS-CoV-2 seroprevalence and understand COVID-19 disease burden in California.
Methods: Between April 2021 and August 2022, 666,857 randomly selected households were invited by mail to complete an online survey and at-home test kit for up to one adult and one child. A gift card was given for each completed survey and test kit. Multiple customized REDCap databases were used to create a data system which provided task automation and scalable data management through API integrations. Support infrastructure was developed to manage follow-up for participant questions and a communications plan was used for outreach through local partners.
Results: Across 3 waves, 32,671 out of 666,857 (4.9%) households registered, 6.3% by phone using an interactive voice response (IVR) system and 95.7% in English. Overall, 25,488 (78.0%) households completed surveys, while 23,396 (71.6%) households returned blood samples for testing. Support requests (n = 5,807) received through the web-based form (36.3%), by email (34.1%), and voicemail (29.7%) were mostly concerned with the test kit (31.6%), test result (26.8%), and gift card (21.3%).
Conclusions: Ensuring a well-integrated and scalable data system, responsive support infrastructure for participant follow-up, and appropriate academic and local health department partnerships for study management and communication allowed for successful rollout of a large population-based survey. Remote data collection utilizing online surveys and at-home test kits can complement routine surveillance data for a state health department.

Keywords: At home testing; Health Department; Population-based surveillance; Remote; SARS-CoV-2.

 
Back
Top Bottom